Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 9,743 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) insider Harpreet Dhaliwal sold 9,743 shares of Vaxcyte stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the sale, the insider directly owned 23,928 shares in the company, valued at approximately $1,117,198.32. The trade was a 28.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Vaxcyte Stock Performance

Shares of PCVX opened at $46.46 on Friday. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $93.77. The stock has a 50-day moving average price of $45.88 and a 200 day moving average price of $38.67. The company has a market capitalization of $6.08 billion, a P/E ratio of -9.60 and a beta of 1.28.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same quarter in the prior year, the business earned ($0.83) earnings per share. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its holdings in shares of Vaxcyte by 5.5% during the first quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock valued at $6,843,000 after purchasing an additional 9,416 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in Vaxcyte by 32.8% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 102,362 shares of the company’s stock valued at $3,328,000 after purchasing an additional 25,303 shares during the period. Intech Investment Management LLC boosted its position in Vaxcyte by 44.3% during the 1st quarter. Intech Investment Management LLC now owns 89,212 shares of the company’s stock valued at $3,369,000 after purchasing an additional 27,384 shares during the period. Strs Ohio bought a new position in Vaxcyte during the 1st quarter worth $627,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Vaxcyte by 5.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,110 shares of the company’s stock worth $459,000 after buying an additional 772 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PCVX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. Leerink Partners set a $77.00 price target on Vaxcyte and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of Vaxcyte in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $97.83.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.